Cutaneous malignant melanoma

Clinical Obstetrics and Gynecology

Volumn 45, Issue 3, 2002, Pages 830-843

  Podczaski, Edward ^a   Cain, Joanna ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MELANOMA; PROGNOSIS; REVIEW; SKIN CARCINOGENESIS;

HUMANS; INCIDENCE; MELANOMA; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0036405202     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200209000-00030     Document Type: Review

References (61)

1. Bennett JP, Hall P. Moles and melanoma: A history. Ann R Coll Surg Engl. 1994;76:373-380.
2. Norris W. A case of fungoid disease. Edinburgh Med Surg J. 1820;16:562-565.
3. Davis NC, McLeod GR. From Hunter to Handley (1787-1907). A retrospective on management approaches to melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998:1-8.
4. Handley WS. The pathology of melanocytic growths in relation to their operative treatment. Lancet. 1907;1:927-933.
5. Friedman RJ, Rigel DS, Silverman MK, et al. Malignant melanoma in the 1990s: The continued importance of early detection and the role of physician examination and self-examination of skin. CA Cancer J Clin. 1991;41:201-210.
6. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
7. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93:824-842.
8. Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: Current practice and surgical controversies. Cur Prob Surg. 1994;31:255-374.
9. Lancaster HO. Some geographical aspects of the mortality from melanoma in Europeans. Med J Aust. 1956;1:1082-1087.
10. Elwood JM, Jopson J. Melanoma and sun exposure: An overview of published studies. Int J Cancer. 1997;73:198-203.
11. Crosby T, Mason M, Crosby D. Malignant melanoma: Non-metastatic. In: Clinical Evidence. London: BMJ Publishing Group, 2001:1175-1182.
12. Greene MH, Clark WH Jr, Tucker MA, et al. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med. 1985;312:91-97.
13. Kraemer KH, Tucker M, Tarone R, et al. Risk of cutaneous melanoma melanoma in dysplastic nevus syndrome types A and B [letter]. N Engl J Med. 1986;315:1615-1616.
14. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation. The Australian experience. Cancer. 1999;85:1758-1764.
15. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
16. Smith CH, McGregor JM, Barker JNWN, et al. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol. 1993;28:51-55.
17. Grob JJ, Bastuji-Garin S, Vaillant L, et al. Excess of nevi related to immunodeficiency: A study in HIV-infected patients and renal transplant recipients. J Invest Dermatol. 1996;107:694-697.
18. Aboulafia DM. Malignant melanoma in an HIV-infected man: A case report and literature review. Cancer Invest. 1998;16:217-220.
19. Ceballos PI, Ruiz-Maldonado R, Mihm MC. Melanoma in children. N Engl J Med. 1995;332:656-662.
20. Egan CL, Oliveria SA, Elenitsas R, et al. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: A follow-up study of 46 patients. J Am Acad Dermatol. 1998;39:923-932.
21. Bale SJ, Dracopli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med. 1989;320:1367-1372.
22. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science. 1990;247:568-571.
23. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-1152.
24. Greene MH. The genetics of hereditary melanoma and nevi. 1998 Update. Cancer. 1999;86:1644-1657.
25. Koh HK, Caruso A, Gage I, et al. Evaluation of a melanoma/skin cancer screening in Massachusetts. Preliminary results. Cancer. 1990;65:375-379.
26. Koh HK, Norton LA, Geller AC, et al. Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. J Am Acad Dermatol. 1996;34:971-978.
27. Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst. 1996;88:17-23.
28. Koh HK, Miller DR, Geller AC, et al. Who discovers melanoma? Patterns from a population-based survey. J Am Acad Dermatol. 1992;26:914-919.
29. Cassileth BR, Temoshok L, Frederick BE, et al. Patient and physician delay in melanoma diagnosis. J Am Acad Dermatol. 1988;18:591-598.
30. Krige JEJ, Isaacs S, Hudson DA, et al. Delay in the diagnosis of cutaneous malignant melanoma. Cancer. 1991;68:2064-2068.
31. Blum A, Brand CU, Ellwanger U, et al. Awareness and early detection of cutaneous melanoma: An analysis of factors related to delay in treatment. Br J Dermatol. 1999;141:783-787.
32. Miller DR, Geller AC, Wyatt SW, et al. Melanoma awareness and self-examination practices: Results of a United States survey. J Am Acad Dermatol. 1996;34:962-970.
33. Federman DG, Concato J, Caralis PV, et al. Screening for skin cancer in primary care settings. Arch Dermatol. 1997;133:1423-1425.
34. Stephenson A, From L, Cohen A, Tipping J. Family physicians' knowledge of malignant melanoma. J Am Acad Dermatol. 1997;37:953-957.
35. Langley RGB, Sober AJ. Clinical recognition of melanoma and its precursors. Hematol Oncol Clin North Am. 1998;12:699-715.
36. Koh HK. Cutaneous melanoma. N Engl J Med. 1991;325:171-182.
37. Langley RGB, Fitzpatrick TB, Sober AJ. Clinical characteristics. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998:81-102.
38. Binder M, Schwarz M, Winkler A, et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol. 1995:131:286-291.
39. Khansur T, Sanders J, Das S. Evaluation of staging workup in malignant melanoma. Arch Surg. 1989;124:847-849.
40. Allen A, Spitz, S. Malignant melanoma. A clinicopathologic analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
41. Petersen N, Bodenham D, Lloyd O. Malignant melanomas of the skin. Br J Plast Surg. 1962;15:49-94.
42. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Can Res. 1969;29:705-727.
43. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
44. Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Hematol Oncol Clin North Am. 1998;12:737-765.
45. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer Staging System for cutaneous melanoma. Cancer. 2000;88:1484-1491.
46. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159-1162.
47. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg. 1993;218:262-269.
48. Slingluff CL, Stidham KR, Ricci WM, et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg. 1994;219:120-130.
49. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the managment of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
50. Veronessi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med. 1977;297:627-630.
51. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age or younger. Ann Surg. 1996;224:255-266.
52. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
53. Messina JL, Glass LF, Cruse CW, et al. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol. 1999;23:686-690.
54. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group EST 1684. J Clin Oncol. 1996;14:7-17.
55. Coit DG. Patient surveillance and follow-up. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998: 313-324.
56. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703-1705.
57. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100β protein in malignant melanoma. Br J Dermatol. 1998;138:426-430.
58. Dale PS, Wang Y, Conrad A, et al. Multiple marker polymerase chain reaction assay for evaluating circulating melanoma cells. Proc ASCO. 1995;14:413.
59. Rajadhyaksha M, Grossman M, Esterowitz D, et al. In vivo confocal scanning laser microscopy of human skin: Melanin provides strong contrast. J Invest Dermatol. 1995;104:946-952.
60. Palmer K, Moore J, Everard M, et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther. 1999;10:1261-1268.
61. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: Recent developments. Oncology. 2001;60:1-7.